Abstract
The use of model‐based drug development (MBDD) has been demonstrated to improve the efficiency of clinical trial design. However, MBDD complexity can limit its use, particularly early in clinical development. In this tutorial, a simple and generalizable exposure‐response analysis approach to determine the power for dose‐ranging studies is presented and described. We identified situations in which higher power and sample size reduction is achieved by utilizing the exposure‐response powering methodology compared with conventional power calculations.
Funding Information
  • AbbVie

This publication has 11 references indexed in Scilit: